Session » Epidemiology & Public Health Poster III

Date: Monday, November 18, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 1882

30-Day Readmission Among Patients with Rheumatoid Arthritis and Their Independent Predictors: Insights from National Readmission Database

10:30AM-12:30PM: Abstract Number: 1871

A Seropositive RA Polygenic Risk Score Does Not Predict Progression to RA in an ACPA Positive Population

10:30AM-12:30PM: Abstract Number: 1869

Analysis of Short-Term Side Effects Following COVID-19 Vaccination in Pregnancies Complicated by Autoimmune Inflammatory Rheumatic Diseases

10:30AM-12:30PM: Abstract Number: 1888

Anti-Spike Antibodies Protect Against COVID-19 Infection in Immune-Mediated Inflammatory Diseases: Findings from the SUCCEED Study

10:30AM-12:30PM: Abstract Number: 1875

Assessing the PULSAR (Program to Understand the Longterm Outcomes in Spondyloarthritis) Registry for Environmental Determinants of Heath Research

10:30AM-12:30PM: Abstract Number: 1895

Association Between a History of Mental Illness and the Risk of Systemic Autoimmune Rheumatic Diseases: A Nationwide, Population-based Case-control Study

10:30AM-12:30PM: Abstract Number: 1891

Association of Physical Activity Levels on Chronic Opioid Use in Radiographic Axial Spondylitis Patients

10:30AM-12:30PM: Abstract Number: 1876

Automated Case Identification of Patients with End-Stage Renal Disease and Systemic Lupus Erythematosus Using Machine Learning

10:30AM-12:30PM: Abstract Number: 1906

Bayesian Algorithm to Identify Osteoarthritis in Administrative Health Data Without Requiring Chart Review

10:30AM-12:30PM: Abstract Number: 1905

Combining Three Peripheral Biomarkers to Stratify Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk

10:30AM-12:30PM: Abstract Number: 1870

Costs and Healthcare Resource Utilization Associated with Inpatient and Day Hospitalizations of Patients with Lupus and Psychiatric Manifestations in France

10:30AM-12:30PM: Abstract Number: 1881

Cross-State Comparative Assessment of Burden of Rheumatoid Arthritis in the United States and It’s Trend from 1990-2021: A Benchmarking Analysis for the Global Burden of Disease Study 2022

10:30AM-12:30PM: Abstract Number: 1894

Detection of Fibrotic Lung Changes and Bronchiectasis in RA Patients Screened for Lung Cancer with Low-dose CT Chest: Results from a Large Multi-hospital System

10:30AM-12:30PM: Abstract Number: 1900

Dietary Exposures Associated with Incident Spondyloarthritis

10:30AM-12:30PM: Abstract Number: 1892

Early Tumor Necrosis Factor Inhibitor Initiation and Chronic Opioid Use in Individuals with Axial Spondyloarthritis

10:30AM-12:30PM: Abstract Number: 1885

Effect of Physical Activity on Mortality in Rheumatoid Arthritis: A Dose-Response Analysis

10:30AM-12:30PM: Abstract Number: 1890

Emergency Department Visits for Ambulatory Care Sensitive Conditions by Persons with Rheumatoid Arthritis: A Population-Based Study

10:30AM-12:30PM: Abstract Number: 1904

Evaluation of the Economic Burden of Psoriatic Arthritis: Assessment of Direct Costs Using National Administrative Databases at National Level

10:30AM-12:30PM: Abstract Number: 1886

Heterogeneity of VEXAS Syndrome: A Multicenter Case-series of 299 Cases from the French VEXAS Study Group (FRENVEX)

10:30AM-12:30PM: Abstract Number: 1887

High Rates of Cost-Related Medication Non-Adherence Among Younger Patients Receiving Immunosuppression Are Exacerbated by Other Chronic Conditions

10:30AM-12:30PM: Abstract Number: 1893

Hydroxychloroquine Use in Early Pregnancy and Risk of Preterm Delivery in a Californian Cohort of Lupus Pregnancy

10:30AM-12:30PM: Abstract Number: 1898

Hyperuricemia Is Associated with Higher Levels of Fasting Plasma Glucose and Insulin Resistance in Non-diabetic Subjects

10:30AM-12:30PM: Abstract Number: 1903

Impact of Multimorbidity on Targeted Synthetic and Biologic Disease-modifying Antirheumatic Drug (ts/bDMARD) Effectiveness in Patients with Rheumatoid Arthritis: A Two Year Follow-up Study from Mexican Adverse Events Registry BIOADAMEX

10:30AM-12:30PM: Abstract Number: 1902

Ixekizumab for the Treatment of Patients with Spondyloarthritis – Real-world Evidence from the Nationwide Danish Registry, DANBIO

10:30AM-12:30PM: Abstract Number: 1872

Nationwide Analysis of Prosthetic Joint Complications with and Without Inflammatory Arthritis

10:30AM-12:30PM: Abstract Number: 1868

Opioid Prescription Rates in Patients with Radiographic Axial Spondyloarthritis in the US Between 2008-2021: A Joinpoint Regression Analysis

10:30AM-12:30PM: Abstract Number: 1897

People Living with Autoimmune Disease Are at Higher Risk of Suffering from Post-Acute Sequelae of SARS-CoV-2 but Immunization Is Protective

10:30AM-12:30PM: Abstract Number: 1889

Prevalence of Physician-Diagnosed versus Clinically Confirmed Primary Sjögren’s Syndrome (SS) Among Adults in the United States

10:30AM-12:30PM: Abstract Number: 1879

Prevalence of Relapsing Polychondritis in Colombia: Data from the National Health Registry 2018 – 2023

10:30AM-12:30PM: Abstract Number: 1883

Psoriatic Arthritis Flare Incidence, Definitions and Risk Factors: A Systematic Review

10:30AM-12:30PM: Abstract Number: 1873

Race/Ethnicity and Household Income at the County Level Interacts with the Association of Urbanicity and Lupus Nephritis Mortality

10:30AM-12:30PM: Abstract Number: 1899

Recurrent Heart Failure Hospitalization in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study

10:30AM-12:30PM: Abstract Number: 1880

Statewide Burden of Osteoarthritis in India and Its Trend from 1990-2021: A Benchmarking Analysis

10:30AM-12:30PM: Abstract Number: 1878

The Associations Between Gout and Ischemic Colitis Among Hospitalized Patients: A Retrospective Nationwide Analysis

10:30AM-12:30PM: Abstract Number: 1896

The Prevalence, Incidence, Risk Factors and Time to Diagnosis of Behcet’s Syndrome in England: A Retrospective Nested Case Control Study in Clinical Practice Research Datalink and Hospital Episode Statistics

10:30AM-12:30PM: Abstract Number: 1877

Trends in Rheumatoid Arthritis Incidence, Prevalence, DALY and Death Rates (1991-2021) in the United States: A Comprehensive Analysis of State-Level Disparities

10:30AM-12:30PM: Abstract Number: 1874

Validation Analysis of the Expanded Risk Score for Rheumatoid Arthritis in a Multicentre Italian Cohort

10:30AM-12:30PM: Abstract Number: 1901

Venous Thromboembolism Risk Is Consistently Increased in People with Rheumatoid Arthritis Across Different Ages, Sexes and Obesity Status: United Kingdom Population Based Study

10:30AM-12:30PM: Abstract Number: 1884

VIVA QI: Vaccination In Vasculitis: Applying a Quality Improvement Approach

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].